Galapagos is applying its functional screening program to the discovery of novel drugable targets in Alzheimer’s disease (AD).
We have developed primary and secondary assays in human cell lines that measure neuronal secretion of Aβ1-42, the primary lesion in AD. SilenceSelect and FLeXSelect are screened in this assay to identify drugable targets that inhibit production of Aβ1-42.These hits are then validated through a selection of secondary validation assays, in order to select a final set of high value novel drugable AD targets for compound screening.

Targets discovered in the Alzheimer’s program are available for licensing. Please contact Galapagos business development for more information.